Metaanálisis de eventos adversos y problemas de medicamentos relacionados a tocilizumab
No hay miniatura disponible
Fecha
2021
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Químicas
Resumen
La Artritis Reumatoide es una enfermedad sistémica autoinmune, cuya característica principal es la de provocar una considerable inflamación en la membrana sinovial que protege y lubrica las articulaciones causando dolor, hinchazón, rigidez y pérdida de funciones, que en los casos más graves, produce una destrucción progresiva con distintos grados de deformidad e incapacidad funcional. Desde hace algunos años, los medicamentos biológicos han sido empleados en el tratamiento de las Enfermedades Reumáticas, los cuales, a pesar de los importantes beneficios que aportan, conllevan efectos secundarios negativos. El objetivo de este trabajo es comparar los Eventos Adversos reportados en la base de datos Uppsala VigiAccess y las Revisiones de Literatura Científica que permitan describir los eventos adversas en el uso del fármaco Tocilizumab, información que no se reporta en la literatura. Se realizó una revisión sistémica de artículos científicos correspondientes a la administración y efectos adversos de Tocilizumab, empleando bases científicas como Google Scholar, ClinicalKey, PubMed, Scopus, y la comparación de eventos adversos reportados en la base de datos VigiAccess. Se identificaron los eventos adversos más relevantes reportados en los Artículos Científicos estableciendo su prevalencia y los problemas relacionados con el medicamento Tocilizumab. Los datos obtenidos según la base VigiAccess indican que la población de entre 40 y 64 años es la más propensa a padecer reacciones adversas a Tocilizumab con un valor de 11.756 casos reportados, esto difiere de lo observado en las publicaciones científicas, en donde el grupo etario de 65 - 74 años fue el más propenso a reacciones adversas seguido por el grupo de 45 - 64 años (3.881 y 581 casos respectivamente). Se recomienda observar el Análisis de los Reportes, para recabar información necesaria a fin de identificar los eventos adversos a medicamentos más comunes, durante los tratamientos con Tocilizumab; desarrollando estrategias informativas y educativas dirigidas al personal de salud y pacientes para su prevención.
Rheumatoid Arthritis is an autoimmune systemic disease, whose main characteristic is to cause considerable inflammation in the synovial membrane that protects and lubricates the joints causing pain, swelling, stiffness and loss of functions, which in the most serious cases, produces destruction progressive with different degrees of deformity and functional disability. For some years now, biological medicines have been used in the treatment of rheumatic diseases, which, despite the important benefits they provide, carry negative side effects. The objective of this work is to compare the Adverse Events reported in the Uppsala VigiAccess database and the Scientific Literature Reviews that allow describing the adverse events in the use of the drug Tocilizumab. A systemic review of scientific articles corresponding to the administration and adverse effects of Tocilizumab was carried out, using scientific bases such as Google Scholar, ClinicalKey, PubMed, Scopus, and the comparison of adverse events reported in the VigiAccess database. The most relevant adverse events reported in Scientific Articles were identified, establishing their prevalence and the problems related to the drug Tocilizumab. The data obtained according to the VigiAccess database indicates that the population between 40 and 64 years of age is the most prone to suffer adverse reactions to Tocilizumab with a value of 11,756 reported cases, this differs from what is observed in scientific publications, where the age group 65-74 years was the most prone to adverse reactions followed by the 45-64 year group (3,881 and 581 cases respectively). It is recommended to observe the Analysis of the Reports, to gather the necessary information to identify the most common adverse events to medications, during the treatments with Tocilizumab; developing informative and educational strategies aimed at health personnel and patients for their prevention.
Rheumatoid Arthritis is an autoimmune systemic disease, whose main characteristic is to cause considerable inflammation in the synovial membrane that protects and lubricates the joints causing pain, swelling, stiffness and loss of functions, which in the most serious cases, produces destruction progressive with different degrees of deformity and functional disability. For some years now, biological medicines have been used in the treatment of rheumatic diseases, which, despite the important benefits they provide, carry negative side effects. The objective of this work is to compare the Adverse Events reported in the Uppsala VigiAccess database and the Scientific Literature Reviews that allow describing the adverse events in the use of the drug Tocilizumab. A systemic review of scientific articles corresponding to the administration and adverse effects of Tocilizumab was carried out, using scientific bases such as Google Scholar, ClinicalKey, PubMed, Scopus, and the comparison of adverse events reported in the VigiAccess database. The most relevant adverse events reported in Scientific Articles were identified, establishing their prevalence and the problems related to the drug Tocilizumab. The data obtained according to the VigiAccess database indicates that the population between 40 and 64 years of age is the most prone to suffer adverse reactions to Tocilizumab with a value of 11,756 reported cases, this differs from what is observed in scientific publications, where the age group 65-74 years was the most prone to adverse reactions followed by the 45-64 year group (3,881 and 581 cases respectively). It is recommended to observe the Analysis of the Reports, to gather the necessary information to identify the most common adverse events to medications, during the treatments with Tocilizumab; developing informative and educational strategies aimed at health personnel and patients for their prevention.
Descripción
Pdf
Palabras clave
ARTRITIS REUMATOIDE, AUTOINMUNE, EVENTOS ADVERSOS, TOCILIZUMAB, VIGIACCESS